| Kimberly Lynch, NP | |
|
5801 S Ellis Ave, Chicago, IL 60637-5418 | |
| (773) 702-1000 | |
| Not Available |
| Full Name | Kimberly Lynch |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 8 Years |
| Location | 5801 S Ellis Ave, Chicago, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417472887 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | 209016242 (Illinois) | Secondary |
| 363L00000X | Nurse Practitioner | 209016242 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The University Of Chicago Medical Center | Chicago, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Chicago | 7719899426 | 1137 |
News Archive
Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has submitted a response letter to the U.S. Food and Drug Administration (FDA) regarding its RIGScan technology Biologic License Application (BLA).
In a new study, researchers report that a class of heart medications called beta-blockers can have a helpful, or harmful, effect on the heart, depending on their molecular activity.
The central nervous system of older individuals responds to movement and initiates muscular contraction differently compared to young individuals.
A man's height is a modest marker for risk of prostate cancer development, but is more strongly linked to progression of the cancer, say British researchers who conducted their own study on the connection and also reviewed 58 published studies.
Soligenix, Inc., a development stage biopharmaceutical company, announced the publication of results from its investigator-initiated Phase 2 "proof-of-concept" exploratory clinical trial of orBec for the prevention of acute Graft-versus-Host disease (GVHD) in patients undergoing myeloablative conditioning regimens with initiation of dosing prior to hematopoietic cell transplantation (HCT) and continuing through the post-transplantation period.
› Verified 4 days ago
| Entity Name | University Of Chicago |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821048786 PECOS PAC ID: 7719899426 Enrollment ID: O20031103000094 |
News Archive
Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has submitted a response letter to the U.S. Food and Drug Administration (FDA) regarding its RIGScan technology Biologic License Application (BLA).
In a new study, researchers report that a class of heart medications called beta-blockers can have a helpful, or harmful, effect on the heart, depending on their molecular activity.
The central nervous system of older individuals responds to movement and initiates muscular contraction differently compared to young individuals.
A man's height is a modest marker for risk of prostate cancer development, but is more strongly linked to progression of the cancer, say British researchers who conducted their own study on the connection and also reviewed 58 published studies.
Soligenix, Inc., a development stage biopharmaceutical company, announced the publication of results from its investigator-initiated Phase 2 "proof-of-concept" exploratory clinical trial of orBec for the prevention of acute Graft-versus-Host disease (GVHD) in patients undergoing myeloablative conditioning regimens with initiation of dosing prior to hematopoietic cell transplantation (HCT) and continuing through the post-transplantation period.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kimberly Lynch, NP 2422 W Lyndale St Apt 1w, Chicago, IL 60647-3361 Ph: (708) 712-3243 | Kimberly Lynch, NP 5801 S Ellis Ave, Chicago, IL 60637-5418 Ph: (773) 702-1000 |
News Archive
Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has submitted a response letter to the U.S. Food and Drug Administration (FDA) regarding its RIGScan technology Biologic License Application (BLA).
In a new study, researchers report that a class of heart medications called beta-blockers can have a helpful, or harmful, effect on the heart, depending on their molecular activity.
The central nervous system of older individuals responds to movement and initiates muscular contraction differently compared to young individuals.
A man's height is a modest marker for risk of prostate cancer development, but is more strongly linked to progression of the cancer, say British researchers who conducted their own study on the connection and also reviewed 58 published studies.
Soligenix, Inc., a development stage biopharmaceutical company, announced the publication of results from its investigator-initiated Phase 2 "proof-of-concept" exploratory clinical trial of orBec for the prevention of acute Graft-versus-Host disease (GVHD) in patients undergoing myeloablative conditioning regimens with initiation of dosing prior to hematopoietic cell transplantation (HCT) and continuing through the post-transplantation period.
› Verified 4 days ago